Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines

Scientific Reports

Volumn 5, Issue , 2014, Pages

  Stolze, Britta ^a   Reinhart, Stefanie ^b   Bulllinger, Lars ^a   Fröhling, Stefan ^b,c   Scholl, Claudia ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; RAS PROTEIN;

CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; HUMANS; MUTATION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84923348272     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08535     Document Type: Article

References (33)

1. Cully, M. & Downward, J. Snap Shot: Ras Signaling. Cell 133, 1292-1292.e1 (2008).
2. Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9, 517-531 (2008).
3. Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310 (2007).
4. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nat Rev Cancer 3, 459-465 (2003).
5. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3, 11-22 (2003).
6. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
7. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013).
8. Roberts, P. J., Stinchcombe, T. E., Der, C. J. & Socinski, M. A. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28, 4769-4777 (2010).
9. Bardelli, A. & Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28, 1254-1261 (2010).
10. Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91, 355-358 (2004).
11. Guerrero, S. et al. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60, 6750-6756 (2000).
12. Janakiraman, M. et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70, 5901-5911 (2010).
13. De Roock, W. et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820 (2010).
14. Tural, D. et al. Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab. Hepatogastroenterology 60, 1035-1040 (2013).
15. Hoa, M., Davis, S. L., Ames, S. J. & Spanjaard, R. A. Amplification of wild-type Kras promotes growth of head and neck squamous cell carcinoma. Cancer Res 62, 7154-7156 (2002).
16. Debnath, J., Muthuswamy, S. K. & Brugge, J. S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268 (2003).
17. Godinho, S. A. et al. Oncogene-like induction of cellular invasion from centrosome amplification. Nature 510, 167-171 (2014).
18. Konishi, H. et al. Knock-in of Mutant K-ras in Nontumorigenic Human Epithelial Cells as a New Model for Studying K-ras Mediated Transformation. Cancer Res 67, 8460-8467 (2007).
19. Roux, P. P. et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282, 14056-14064 (2007).
20. Haigis, K. M. & Sweet-Cordero, A. New insights into oncogenic stress. Nat Genet 43, 177-178 (2011).
21. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol 7, 131-142 (2006).
22. Soule, H. D. et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50, 6075-6086 (1990).
23. Charafe-Jauffret, E. et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25, 2273-2284 (2005).
24. Smid, M. et al. Subtypes of Breast Cancer Show Preferential Site of Relapse. Cancer Res 68, 3108-3114 (2008).
25. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874 (2001).
26. Hoadley, K. A. et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8, 258 (2007).
27. Ancrile, B. B., O'Hayer, K. M. & Counter, C. M. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol Interv 8, 22-27 (2008).
28. Yang, G. et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 103, 16472-16477 (2006).
29. Wislez, M. et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 66, 4198-4207 (2006).
30. Sunaga, N. et al. Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. Br J Cancer 110, 2047-2053 (2014).
31. Sanchez-Laorden, B. et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal 7, ra30 (2014).
32. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834 (2009).
33. Scholl, C. et al. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. Genes Chromosomes Cancer 38, 274-280 (2003).